Discontinuation of Canakinumab following Clinical Disease Remission Is Feasible in Patients with Systemic Juvenile Idiopathic Arthritis.

Maritsi, Despoina N; Vougiouka, Olga; Eleftheriou, Despina

Maritsi, Despoina N; Vougiouka, Olga; Eleftheriou, Despina.

Afiliación

Maritsi DN; Infectious Diseases, Immunology and Rheumatology Unit, Second Department of Paediatrics, P. & A. Kyriakou Children's Hospital, Medical School, National and Kapodistrian University of Athens, and Pediatric Faculty, Medical School, University of Cyprus, Nicosia, Cyprus; dmaritsi@gmail.com.
Vougiouka O; Infectious Diseases, Immunology and Rheumatology Unit, Second Department of Paediatrics, P. & A. Kyriakou Children's Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece.
Eleftheriou D; UCL-Great Ormond Street-Institute of Child Health, Infection, Immunity, Inflammation and Physiological Medicine, London, UK.

J Rheumatol ; 47(4): 634-635, 2020 04.

Article en En | MEDLINE | ID: mdl-32062604

Asunto(s)

Antirreumáticos; Artritis Juvenil; Anticuerpos Monoclonales Humanizados/uso terapéutico; Antirreumáticos/uso terapéutico; Artritis Juvenil/tratamiento farmacológico; Humanos

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Artritis Juvenil / Antirreumáticos Límite: Humans Idioma: En Revista: J Rheumatol Año: 2020 Tipo del documento: Article

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google